InCarda Therapeutics CEO and leadership

Biotechnology executive with over 25 years experience in biopharma, genomics, health care, venture capital, management consulting, entrepreneurship, and industrial biotechnology. Strong business and technical background, and proven leadership, communication and organizational skills. Experienced for-profit (public and private) and non-profit board director. Frequent speaker, moderator and panelist.Specialties: Therapeutics, medical devices, drug/device combinations, genomics, proteomics, microbiome, diagnostics, synthetic biology, digital health. Strategic, portfolio and operational planning, project and resource management, strategic marketing, alliance management, business development, clinical operations, product development and commercialization, venture capital, fundraising, entrepreneurship, start-up formation and scale-up. From San Juan, Puerto Rico; mom of three teenagers (no, wait - one of them just turned 20...); runner, SCUBA diver, paddle boarder, rabid fan of golden age as well as modern science fiction, occasionally semi-competent singer, obsessive sea glass collector, and aspiring juggler.Twitter: @ColonGraceEClubhouse: @gracecolonInstagram: gracielaelenacolon

Carlos Schuler is a Chief Operating and Technology Officer at InCarda Therapeutics and is based in San Francisco Bay Area. He has worked as Vice President, CMC at Anesiva Inc; Associate Technical Director at Nektar Therapeutics; and Senior Director of Science and Technology, in charge of Applied Research and Process Development at Nektar Therapeutics. Carlos works or has worked as Co-founder and CTO at InCarda Therapeutics. He attended University of California Berkeley between 1987 and 1991, Liceo Los Arcos between 1972 and 1978, and Universidad Nacional Experimental Simón Bolívar between 1983 and 1985.

Luiz Belardinelli is a Chief Medical Officer at InCarda Therapeutics, VP:Drug Res & Pharm Sciences at CV Therapeutics Inc, and Senior VP:Cardiovascular at GILEAD SCIENCES INC. He has worked as Exec VP at CV Therapeutics Inc.

Carlos Schuler is a Chief Operating and Technology Officer at InCarda Therapeutics and is based in San Francisco Bay Area. He has worked as Vice President, CMC at Anesiva Inc; Associate Technical Director at Nektar Therapeutics; and Senior Director of Science and Technology, in charge of Applied Research and Process Development at Nektar Therapeutics. Carlos works or has worked as Co-founder and CTO at InCarda Therapeutics. He attended University of California Berkeley between 1987 and 1991, Liceo Los Arcos between 1972 and 1978, and Universidad Nacional Experimental Simón Bolívar between 1983 and 1985.

Biotechnology executive with over 25 years experience in biopharma, genomics, health care, venture capital, management consulting, entrepreneurship, and industrial biotechnology. Strong business and technical background, and proven leadership, communication and organizational skills. Experienced for-profit (public and private) and non-profit board director. Frequent speaker, moderator and panelist.Specialties: Therapeutics, medical devices, drug/device combinations, genomics, proteomics, microbiome, diagnostics, synthetic biology, digital health. Strategic, portfolio and operational planning, project and resource management, strategic marketing, alliance management, business development, clinical operations, product development and commercialization, venture capital, fundraising, entrepreneurship, start-up formation and scale-up. From San Juan, Puerto Rico; mom of three teenagers (no, wait - one of them just turned 20...); runner, SCUBA diver, paddle boarder, rabid fan of golden age as well as modern science fiction, occasionally semi-competent singer, obsessive sea glass collector, and aspiring juggler.Twitter: @ColonGraceEClubhouse: @gracecolonInstagram: gracielaelenacolon